Early Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years of any gender
• People who have been confirmed through laboratory testing of tissue or cell samples to have a type of kidney cancer called clear cell renal cell carcinoma that cannot be removed by surgery or has spread to other parts of the body
• People whose cancer has continued to grow or spread after receiving at least two previous treatments, including at least one immunotherapy drug and at least one targeted therapy drug that works on blood vessel growth
• People who are willing to have a tumor tissue sample taken, or who can provide a previously collected tumor sample, so it can be tested for a specific protein called CD70
• People whose tumor tissue tests positive for the CD70 protein, meaning at least 10% of the tested cancer cells show this protein
• People who have at least one area of cancer that can be measured using standard imaging criteria
• People whose general health and ability to carry out daily activities meets a minimum score on the Karnofsky Performance Scale (a score of 70% or higher) (confirm with trial site)
• People whose blood counts, blood clotting, liver, kidney, heart, and lung function all meet specific minimum levels as measured by standard tests (confirm with trial site for exact values)
• People who agree to use effective contraception throughout the entire treatment period and for 52 weeks after treatment ends, and who agree not to donate eggs or sperm during this time
• Women who could become pregnant must have a negative pregnancy test at the start of the trial and agree to use effective contraception throughout the study
• People who are willing to follow all study procedures and who give their written consent to participate

Who may not be able to join:

• People whose life expectancy is estimated to be less than 3 months
• People who have, or have had, another cancer — unless it has been fully treated and has not returned for at least 3 years (some exceptions apply for certain low-risk cancers such as early-stage skin cancers or specific localised cancers that were treated with curative intent)
• People who have previously received any treatment that specifically targets the CD70 protein
• People who have previously received CAR-T cell therapy or any other type of genetically engineered cell therapy
• People who have a history of significant brain or nervous system conditions, such as stroke, bleeding in the brain, epilepsy, dementia, or similar conditions
• People who have had a major organ transplant (such as heart, lung, kidney, or liver) or a bone marrow or stem cell transplant
• People who have had a heart attack, heart procedure, stent placement, unstable chest pain, or other serious heart conditions within the 12 months before joining the trial
• People who have cancer that has spread to the brain, or who have symptoms suggesting this
• People who still have significant side effects from previous cancer treatments that have not yet returned to a mild or resolved level (with some exceptions such as hair loss)
• People who have recently received other anti-cancer treatments and have not yet waited the required time before the study drug can be given (confirm with trial site)
• People who have an active infection — bacterial, fungal, viral, or other — that is not under control
• People who test positive for HIV, syphilis, active hepatitis B, or active hepatitis C (some exceptions may apply if the infection can be safely managed with medication, as determined by the treating doctor)
• People who have a history of autoimmune diseases that require ongoing treatment with immune-suppressing medications
• People who are known to have a severe allergy to the study drug or any of its ingredients
• People who are pregnant or breastfeeding
• People who have received a live vaccine within 6 weeks before the preparatory treatment given before the study drug infusion
• People who are currently taking part in another interventional clinical trial or who received an experimental drug within 3 months before signing consent for this trial
• People who have a psychiatric condition involving depression or suicidal thoughts
• People who have any other medical condition that could affect how safely or accurately the study drug can be evaluated
• People who are considered unsuitable for any other reason, as determined by the treating doctor at the trial site

Important: Always verify eligibility with the trial site directly before applying.